ClinicalTrials.gg
CompletedNCT05592392Updated Sep 22, 2025

RECOVER-HF Pilot Study of SDS in Heart Failure

An interventional study of Synchronized Diaphragmatic Stimulation in Heart Failure With Reduced Ejection Fraction, sponsored by VisCardia Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by VisCardia Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Heart Failure with a site in Georgia — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure · Georgia.

Enrollment
26th of 44
35 · median 50
Started
2022
with 3 others
No phase
25 of 46
15 open now
Registered
29th of 46
by date
Lead sponsor
3 of 46
VisCardia Inc.

Among the 46 studies in Heart Failure with a site in Georgia, this one is the 26th largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2022, is one of 25 with no phase, and was the 29th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

18 of the 46 studies in Heart Failure with a site in Georgia are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Heart Failure with a site in Georgia, or all of them as a file.
02

Study summary

The RECOVER HF pilot is a feasibility study for evaluating a randomized, doubled-blinded study design to determine the benefits and risks of chronically delivering Synchronized Diaphragmatic Stimulation (SDS) in Heart Failure patients on GDMT with NYHA II/III, EF\<=40% and QRSd,=130ms.

Read the detailed description

Symptomatic Diaphragmatic Stimulation (SDS) is a novel approach designed to improve cardiac function, symptoms, and, ultimately, outcomes for patients who are symptomatic for heart failure.

Elevated intracardiac pressures are the hallmark of heart failure (HF) and a key pathological driver of disease progression and limited exertional capacity. The degree of cardiac pressure elevation is determined by preload, afterload, and pericardial restraint. The pericardium restrains the heart, and the degree of restraint is determined by the pericardial structure itself and the intrathoracic pressure. This aspect of HF pathophysiology is among the fundamental drivers behind the SDS therapy concept. SDS induces a temporal modulation of intrathoracic pressure with a resultant reduction in pericardial restraint, leading to improved cardiac filling and reduced afterload. When applied at the right time in the cardiac cycle, SDS can improve cardiac filling, cardiovascular pressure conditions, and systolic cardiac performance.

Encouraged by the results of the VisONE HF study pilot (NCT03484780), SDS shall now be further valuated in a randomized controlled trial (RCT) pilot. This RCT pilot has three objectives: two semi-acute items (15-30 days) verification of sensing function using the modified input filters and improved usability based on increased automaticity of the user-interface; and one chronic result (6 months) to reproduce similar efficacy endpoints. The herein described study is a pilot trial for a larger RCT trial.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Keywords

  • Heart Failure
  • Heart Disease
  • Cardiovascular Diseases
  • Synchronized Diaphragmatic Stimulation
  • Implantable Heart Failure Device Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • classes II/III on optimal Guideline Directed Medical Therapy
  • QRS duration ≤ 130 ms
  • \< 40%
  • Willing and able to comply with protocol requirements, including attending all required visits
  • Wiling to participate in the study and able to sign an form

Exclusion criteria

Exclusion Criteria:

  • Baseline 6-minute walk test > 500 meters or \< 200 meters
  • NT-proBNP\< 250 if on loop diuretics, or NT-proBNP \< 500 if not on loop diuretics
  • Supine resting heart rate > 140 bpm
  • Systolic blood pressure \< 80 mmHg or > 170 mmHg
  • Serum creatinine > 2.5 mg/dL
  • Serum hepatic function 3x
  • Unstable angina, AMI, CABG, PTCA, CVA/, persistent AF, NSVT or DCCV within 3 months
  • Intermittent IV inotropic drug treatment
  • Arrhythmias present during screening (profound ectopy, bradycardia, profound prevalence of ectopy, NSVT, VF, AF*, SVT or AFLT) - * see enrollment exception allowing for 10 patients in AF for a separate subgroup analysis
  • Reversible non-ischemic cardiomyopathy
  • Primary valvular disease
  • Severe primary pulmonary disease, including pulmonary arterial hypertension. PAP sys >70 mmHg at rest
  • Severe , other respiratory or lung diseases where FEV \< 50%
  • Pericardial disease
  • Diabetic neuropathy
  • Existing diaphragmatic stimulation for respiration assist
  • LVAD or other mechanical cardiac assist devices
  • to laparoscopic access to the diaphragm, as determined by the implanting physician
  • Known intra-abdominal pathology which could increase the risk of laparoscopic access to the diaphragm.
  • Previous open laparotomy within 1 year
  • Previous thoracic or abdominal organ transplant
  • Drug induced immuno-suppression
  • > 40
  • Enrollment in a concurrent investigation / clinical study
  • Having a of \<1 year due to any condition
  • Pregnant or planning a pregnancy during the study period
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Therapy

    SDS system implanted and Therapy On for 6 months post randomization

    Device: Synchronized Diaphragmatic Stimulation

  • Sham comparator
    Control

    SDS system implanted and Therapy Off for 6 months post randomization

    Device: Synchronized Diaphragmatic Stimulation

Interventions

  • DeviceSynchronized Diaphragmatic Stimulation

    Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.

    Also known as: ADS, SDS, VisONE SDS

06

What researchers measure

Primary outcomes

  1. Change in LVESV

    Change from baseline in left ventricular end systolic volume (LVESV) post-randomization between the control group and the therapy group.

    Time frame: 6 months

  2. Freedom from VisONE device-related and procedure-related Major Adverse Respiratory and Cardiovascular Events (MARCE) after the index implantation procedure

    The following Major Respiratory and Cardiovascular Events will be analyzed for their rate and severity and association with the implantable device or procedure: 1. CV Death 2. Stroke 3. Cardiac Arrest 4. Interaction with cardiac rhythm device requiring permanent termination of SDS therapy 5. Acute Heart Failure Decompensation 6. Infection requiring device/lead explant 7. Diaphragmatic dysfunction leading to a clinically significant reduction is respiratory function 8. Inadequate SDS therapy delivery requiring surgical intervention 9. Injury to abdominal organs requiring surgical intervention 10. Pneumothorax 11. Hemothorax 12. Peritonitis

    Time frame: 12 months

Secondary outcomes

  1. Change in 6MHW distance

    Change from baseline in 6 MHW distance post-randomization between the control group and the therapy group.

    Time frame: 6 months

  2. Change in MLWHF overall score

    Change from baseline in MLWHF total score post-randomization between the control group and the therapy group.

    Time frame: 6 months

07

Study locations

2 sites
  • Tbilisi Heart And Vascular Clinic
    Tbilisi, 0159, Georgia
  • Republican Specialized Scientific and Practical Medical Center for Surgery n.a. V. Vakhidov
    Tashkent, 100115, Uzbekistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Sep 2024, 25 months.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 25 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2022
First posted
Oct 24, 2022
StartActual
Aug 23, 2022
Primary completionActual
Sep 30, 2024
CompletionActual
Feb 28, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05592392
Lead sponsor
VisCardia Inc.
Collaborators
Clinical Accelerator
Responsible party
Sponsor
First posted
Oct 24, 2022
Start date
Aug 23, 2022
Primary completion
Sep 30, 2024
Completion
Feb 28, 2025
Last update
Sep 22, 2025

Study contacts

Tamaz Shaburishvili, MD, PhD
principal investigator · Tbilisi Heart and Vascular Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion